Monthly MS injection studied, but trial halted early
NCT ID NCT03362294
First seen Apr 23, 2026 · Last updated May 22, 2026 · Updated 4 times
Summary
This study tested a long-acting monthly injection of glatiramer acetate in 30 adults with primary progressive multiple sclerosis (MS). The goal was to see if it could safely slow down worsening disability. The trial was stopped early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mapi Pharma Research site 01
Tel Aviv, Israel
-
Mapi Pharma Research site 06
Rehovot, Israel
-
Mapi Pharma Research site 07
Jerusalem, Israel
-
Mapi Pharma Research site 08
Petah Tikva, Israel
-
Mapi Pharma Research site 09
Haifa, Israel
-
Mapi Pharma Research site 20
Chisinau, Moldova
-
Mapi Pharma Research site 22
Chisinau, Moldova
Conditions
Explore the condition pages connected to this study.